Compare ATYR & PFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATYR | PFL |
|---|---|---|
| Founded | 2005 | 2003 |
| Country | United States | United States |
| Employees | 59 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.3M | 379.3M |
| IPO Year | N/A | 2003 |
| Metric | ATYR | PFL |
|---|---|---|
| Price | $0.84 | $8.00 |
| Analyst Decision | Hold | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $4.20 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 195.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.53% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9,628.95 | N/A |
| Revenue Next Year | $156.94 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.64 | $7.11 |
| 52 Week High | $7.29 | $8.70 |
| Indicator | ATYR | PFL |
|---|---|---|
| Relative Strength Index (RSI) | 43.50 | 26.54 |
| Support Level | $0.82 | N/A |
| Resistance Level | $0.85 | $8.49 |
| Average True Range (ATR) | 0.07 | 0.08 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 7.78 | 4.12 |
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
PIMCO Income Strategy Fund is a United States-based closed-end management investment company. The fund's investment objective is to seek high current income, consistent with the preservation of capital. The company seeks to achieve its objectives by investing in a diversified portfolio of floating and fixed-rate debt instruments.